Early kynurenergic impairment in Huntington's disease and in a transgenic animal model (Q28375944)

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Increase in kynurenic acid in Huntington's disease motor cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Activated human microglia produce the excitotoxin quinolinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Blood?Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Quantification of 3-hydroxykynurenine in brain by high-performance liquid chromatography and electrochemical detection

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Human microglia convert l-tryptophan into the neurotoxin quinolinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Brain quinolinic acid in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Kynurenic acid-enhancing and anti-ischemic effects of the potent kynurenine 3-hydroxylase inhibitor FCE 28833 in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021

Neuropathological classification of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2800%2900956-3

7 January 2021